Navigation Links
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Date:4/2/2009

efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... bioLytical Laboratories Inc. announced ... was accepted for presentation at the 8th Annual International AIDS Society (IAS) Conference ... Wednesday, July 22nd from 1:00 pm to 2:00pm Pacific Standard Time at the ...
(Date:7/7/2015)... ... , ... uBiome, the leading microbial genomics company, is offering talented researchers with ... 16S laboratory analysis. The goal is to fast-track a study with the greatest potential ... own dashboard, enabling them to view and compare the results of their study, as ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia ... to innovation in life science R&D, has attracted a number of new members ... top ten pharmaceutical company joining as a Core member, and DNAnexus and Tessella ...
(Date:7/6/2015)... 6, 2015  Emdeon Inc. today announced ... agreement to acquire Altegra Health, a national ... combine data aggregation and analytics with unique ... actionable insights and improved management for value-based ... risk adjustment and quality analytics and Emdeon,s ...
Breaking Biology Technology:bioLytical to Present Findings of Early HIV Detection 2bioLytical to Present Findings of Early HIV Detection 3uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3Pistoia Alliance Continues to Attract New Members 2Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. ... Officer of BioMarin, will present a company update at the Morgan Stanley ... 1:35 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SAN DIEGO, Sept. 8 eBioscience Corporation, a ... the acquisition of NatuTec GmbH, a leading distributor of high-quality biological ... , "For the past 10 years, NatuTec has ... R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides eBioscience ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... a,U.S. pharmaceutical company with its principal operations in the ... for,fiscal year 2009. The Company expects to meet ... revenue and operating income of $40 to $43 million ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... in the Southampton Centre for Biomedical Research, established ... (SUHT) and the University of Southampton, have been ... and respiratory research facilities. The funding, ... investment in NHS and university partnerships, has secured ...
... of celiac disease in women who present with unexplained ... The Journal of Reproductive Medicine, the study ... participant underwent serologic screening for celiac disease as well ... had positive serum test results were advised to seek ...
... of revising now that biologists at UC San Diego have ... According to the textbooks, chromatin, the natural state of DNA ... nucleosomes are the basic repeating unit of chromatin. When ... on a string (photo at right). But in the August ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2Biologists' discovery may force revision of biology textbooks 2
...
Rubeola (Measles) Antigen Preservative: No Preservatives...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
Biology Products: